Valuation: Waverley Pharma Inc.

Market Cap 1.35M 950K 832K 763K 712K 90.46M 1.37M 9.17M 3.56M 44.47M 3.57M 3.49M 153M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.75M 3.34M 2.93M 2.68M 2.51M 318M 4.82M 32.25M 12.52M 156M 12.56M 12.29M 540M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 month+150.00%
3 months+66.67%
6 months+25.00%
Current year+25.00%
1 month 0.02
Extreme 0.015
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.14
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 2020-01-31
Director of Finance/CFO - 2019-12-31
Director TitleAgeSince
Chairman 79 2016-12-13
Director/Board Member 54 2016-12-13
Director/Board Member - 2023-11-21
Date Insider Type Main position Quantity % Market Cap.
24-06-23Other

Director

0 0%
21-08-17Other

Chairman

0 0%
21-08-17Option

Chairman

10,000,000 18.5185%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-37.50% 952K
+0.68%+6.27%+77.60%+133.76% 58.73B
+2.32%+5.89%+76.81%+99.20% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.47%+46.43%+0.03% 18.8B
-0.29%+8.57%+44.17%-27.58% 17.61B
0.00%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+20.94%+51.67% - 13.9B
Average +2.58%+6.45%+49.76%+126.16% 24.21B
Weighted average by Cap. +2.44%+5.53%+59.06%+137.34%

Financials

2024 2025
Net sales 475K 335K 293K 269K 251K 31.85M 483K 3.23M 1.25M 15.66M 1.26M 1.23M 54.02M 1.35M 950K 831K 763K 712K 90.44M 1.37M 9.16M 3.56M 44.46M 3.57M 3.49M 153M
Net income -947K -667K -583K -535K -500K -63.46M -962K -6.43M -2.5M -31.2M -2.5M -2.45M -108M -499K -351K -308K -282K -263K -33.45M -507K -3.39M -1.32M -16.45M -1.32M -1.29M -56.73M
Net Debt 2.83M 1.99M 1.74M 1.6M 1.49M 190M 2.88M 19.22M 7.46M 93.24M 7.48M 7.32M 322M 3.4M 2.39M 2.09M 1.92M 1.79M 228M 3.45M 23.08M 8.96M 112M 8.99M 8.79M 386M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
26-06-29 $0.000000 - 100
26-06-25 $0.000000 -100.00% 200
  1. Stock Market
  2. Stocks
  3. WAVE Stock